title: [Experience with rivaroxaban and dabigatran].
authors.forename: V
authors.initials: V
authors.lastname: Aumann
authors.forename: N
authors.initials: N
authors.lastname: Boxberger
authors.forename: M U
authors.initials: MU
authors.lastname: Heim
authors.forename: K-J
authors.initials: KJ
authors.lastname: Hartung
authors.forename: A
authors.initials: A
authors.lastname: Siegemund
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage; D000991:Antithrombins / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage*; D000069604:Dabigatran; D004359:Drug Therapy, Combination; D005260:Female; D006470:Hemorrhage / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage*; D020151:Protein C Deficiency / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D000069552:Rivaroxaban; D000069604:Dabigatran